VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | Treatment strategies for cHL patients after auto-HSCT

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses different treatment strategies for patients with classical Hodgkin lymphoma (cHL) that relapse or progress after autologous-hematopoietic stem cell transplant (auto-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter